ERBB2 and breast carcinoma: Due to a decline in left ventricular ejection fraction, the patient continued with trastuzumab to complete 1 year of HER2-targeted therapy.[7] Additionally, Matsumoto et al presented a case of breast cancer with liver metastasis in a patient who underwent hemodialysis.